'In 2015 BMS snapped up a preclinical immuno-oncology small molecule asset from CA-based Flexus for US$1.25Bil with US$800Mil cash upfront. We are particularly excited about this agreement because we believe we can apply our core expertise in tumor immunology to rapidly advance our potent and selective small-molecule arginine modulators into the clinic to develop a first-inclass immuno-oncology therapy for cancer patients.'
Progress !, page-62
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
0.001(1.02%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.8¢ | $223.2K | 4.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 641018 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 6544392 | 38 |
View Market Depth
| Last trade - 14.24pm 01/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |